Vídeo

DCGI approves phase 2, 3 trials of ‘Covaxin’ on 2 to 18 year-olds

DCGI approves phase 2, 3 trials of ‘Covaxin’ on 2 to 18 year-olds
Drugs Controller General of India (DCGI) gave nod to Hyderabad-based Bharat Biotech's 'Covaxin' for phase 2 and 3 trials on 2 to 18 year-olds on May 13. The trial will be conducted in 525 healthy volunteers. In the ongoing vaccination drive in India, the 'Covaxin' is being used in adults. 'Covaxin' is one of the two vaccines being manufactured in India currently.